Since the announcement of the transaction on January 3, 2019, a number of concrete advances have been made in the implementation of the main drivers of the merger, including: further advances in the patent application for REVLIMID®, approval of INREBIC® (Fedratinib) by the U.S. Food and Drug Administration (FDA) for the treatment of certain forms of myelofibrosis, U.S. FDA clearance of REBLOZYL® (luspatercept-aamt) for the treatment of besti anemia in adult patients with beta-thalassemia, and applications for approval of luspatercept and Ozanimod in the United States and Europe. The company has also made substantial progress in planning for a successful integration. You will find an overview of the combined company and the steps that have been taken during the ongoing operation www.bestofbiopharma.com. Effective January 2 On January 1, 2019, Celgenes Chief Executive Officer, Chief Financial Officer, President, Research & Early Development and Chief Corporate Strategy Officer have become participants in the Celgene Corporation Executive Severance Plan (ESP). According to the PESE, each of these executives is entitled to severance pay in the event of termination of the employment contract by the company, without justification or because of the resignation of the director for cause (a “qualifying dismissal” each), subject to the execution of a dismissal and cancellation agreement. These two have criticized the FTC`s approach to pharmaceutical merger investigations, which are typically resolved by selling competing lines to other pharmaceutical companies. This framework is too narrow and could miss other ways for massive pharmaceutical operations to harm competition, they said. As a result of the 26th, Bristol-Myers has now met all regulatory requirements under the merger agreement concluding the celgene acquisition and expects the transaction to close on November 20, 2019. . .
